Drug intelligence / Profile preview

[18F]AmBF3-PEG4-TOC

Development stage: Unknown
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
Administration: Intravenous

Overview

**[18F]AmBF3-PEG4-TOC** is a novel radiolabeled peptide tracer designed for positron emission tomography (PET) imaging. It consists of an octreotide analog (TOC) modified with a tetraethylene glycol (PEG4) linker and radiolabeled with fluorine-18 via an ammoniomethyltrifluoroborate ([18F]AmBF3) prosthetic group through bioorthogonal chemistry. The compound targets somatostatin receptor subtype 2 (SSTR2), which is highly expressed in neuroendocrine tumors. Preclinical studies demonstrate its favorable in vivo stability, rapid clearance from non-target tissues, and clear tumor visualization in animal models, making it a promising candidate for PET imaging of SSTR2-expressing tumors[1][3][4].

Other names: [18F]AmBF3-PEG4-TOC

Targets

SSTR2 (Somatostatin receptor type 2)

Beyond the preview

Go deeper on [18F]AmBF3-PEG4-TOC.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on [18F]AmBF3-PEG4-TOC.

Explore the full profile